Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy-Reference-Cited by-同舟云学术

Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy

Published:2019-07-08 Issue:19 Volume:25 Page:5890-5900
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Karches Clara H.,Benmebarek Mohamed-Reda,Schmidbauer Moritz L.,Kurzay Mathias,Klaus Richard,Geiger Martina,Rataj Felicitas,Cadilha Bruno L.,Lesch Stefanie,Heise Constanze,Murr Ramona,vom Berg Johannes,Jastroch Martin,Lamp Daniel,Ding Jian,Duewell Peter,Niederfellner Gerhard,Sustmann Claudio,Endres Stefan,Klein Christian,Kobold Sebastian

Funder

European Commission (EC)

EC | European Research Council (ERC)

Jung-Stiftung für Wissenschaft und Forschung (Jung-Stiftung)

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Universal CAR 2.0 to overcome current limitations in CAR therapy;Frontiers in Immunology;2024-06-19

2. Fully equipped CARs to address tumor heterogeneity, enhance safety, and improve the functionality of cellular immunotherapies;Frontiers in Immunology;2024-06-03

3. PD-1 blockade does not improve efficacy of EpCAM-directed CAR T-cells in lung cancer brain metastasis.;2024-06-03

4. The present and future of bispecific antibodies for cancer therapy;Nature Reviews Drug Discovery;2024-03-06

5. Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia;Nature Communications;2024-02-02